Therapeutic Applications of Curcumin Nanoformulations

Yallapu, Murali M.; Nagesh, Prashanth K.B.; Jaggi, Meena; Chauhan, Subhash C.

doi:10.1208/s12248-015-9811-z

Cited by 301 publications

(195 citation statements)

References 133 publications

Supporting

Mentioning

187

Contrasting

Unclassified

Order By: Relevance

“…The problem with NP-mediated miRNA and/or drugs is that uptake by cancer cells is not specific; however, this can be circumvented utilizing targeted approaches by coating the surface of NPs with specific antibodies or ligands against proteins that are specifically expressed in cancer cells. The targeted delivery of curcumin (a natural product) was shown in C4-2 prostate cancer cell-derived xenograft tumors using PLGA NPs conjugated with I-131-labeled PSMA antibody [68,69]. These results showed significantly reduced prostate tumor burden, and the efficient delivery of curcumin to targeted prostate tumors with reduced or no uptake by other organs.…”

Section: Targeted Drug Delivery Systemmentioning

confidence: 99%

miRNA nanotherapeutics for cancer

Ganju

Khan

Hafeez

et al. 2017

Drug Discovery Today

Self Cite

253

165

View full text Add to dashboard Cite

miRNAs are noncoding RNA molecules that regulate gene expression through diverse mechanisms. Increasing evidence suggests that miRNA-based therapies, either restoring or repressing miRNA expression and activity, hold great promise. However, the efficient delivery of miRNAs to target tissues is a major challenge in the transition of miRNA therapy to the clinic. Cationic polymers or viral vectors are efficient delivery agents but their systemic toxicity and immunogenicity limit their clinical usage. Efficient targeting and sustained release of miRNAs/anti-miRNAs using nanoparticles (NPs) conjugated with antibodies and/or peptides could reduce the required therapeutic dosage while minimizing systemic and cellular toxicity. Given their importance in clinical oncology, here we focus on the development of miRNA nanoformulations to achieve enhanced cellular uptake, bioavailability, and accumulation at the tumor site.

show abstract

Section: Targeted Drug Delivery Systemmentioning

confidence: 99%

miRNA nanotherapeutics for cancer

Ganju

Khan

Hafeez

et al. 2017

Drug Discovery Today

Self Cite

253

165

View full text Add to dashboard Cite

show abstract

“…one thousand) of nanoformulations have been undertaken to enhance curcumin use in in vitro, in vivo, preclinical, and clinical settings that involve the use of nanogels, and a plethora of lipid and hydrophilic nanocarriers, i.e., polymeric nanoparticles, liposomes, micelles, nanoemulsions, CD complexes, nanodisks, nanofibers, solid lipid nanoparticles, and solid nanodispersions. The specific roles and advantages of each delivery system are reported in a very comprehensive and recent review [44]. Many of these efforts initially dealt with improved bioavailability, but newer formulations pay attention to efficient targeting of curcumin at the diseased area with the aid of antibody, aptamer, and peptide mediation [44].…”

Section: Curcumin-loaded Nanoparticles: Increased Efficacy Of a Plethmentioning

confidence: 99%

“…The specific roles and advantages of each delivery system are reported in a very comprehensive and recent review [44]. Many of these efforts initially dealt with improved bioavailability, but newer formulations pay attention to efficient targeting of curcumin at the diseased area with the aid of antibody, aptamer, and peptide mediation [44].…”

Section: Curcumin-loaded Nanoparticles: Increased Efficacy Of a Plethmentioning

confidence: 99%

Improving on Nature: The Role of Nanomedicine in the Development of Clinical Natural Drugs

et al. 2017

View full text Add to dashboard Cite

Natural products have been used as a major source of drugs for millennia, and about half of the pharmaceuticals in use today are derived from natural products. However, their efficacy can be limited because of their low hydrophilicity and intrinsic dissolution rate(s), or physical/chemical instability. In addition, they can present scarce absorption, poor pharmacokinetics and bioavailability, scarce biodistribution, first-pass metabolism, trivial penetration and accumulation in the organs of the body, or low targeting efficacy. Novel nanoformulations based on drug delivery systems, namely nanoparticles, micelles, and vesicles, offer significant promise in overcoming these limitations. Nowadays, nanomedicine is crucial in developing appropriate therapeutic treatments of essential drugs, specifically antitumor and antiparasistic agents (i.e., Taxol, vincristine, camptothecin, doxorubicin, artemisinin) and other emerging molecules with pleiotropic functions (i.e., resveratrol, curcumin, salvianolic acid B, honokiol). Additionally, the number of nanoformulations developed with flavonoids, in particular rutin, quercetin, silymarin, and green tea catechins, is constantly increasing, and a significant number of publications have appeared in the last decade pertaining to nanoformulations based on extracts and essential oils. Most of these studies report very promising nanoformulations with sustained release and improved bioavailability at much lower doses than conventional preparations, and in many cases, also a better safety profile.

show abstract

“…The clinical implication of native curcumin is hindered due to low solubility, physico-chemical instability, poor bioavailability, rapid metabolism, and poor pharmacokinetics. Therefore, there is a need to improve curcumin's pharmacokinetics, systemic bioavailability, and biological activity which can be done by encapsulation curcumin or by loading into nanoform(s) [32].…”

Section: Other Common Food Nutraceuticalsmentioning

confidence: 99%